1. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects;Eriksson;Eur J Clin Pharmacol,2003
2. NDA 21-686, Ximelagatran (H376/95). Available at: http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4069S1_01_A-Astra-Zeneca-Introduction.pdf. Accessed March 20 2005.
3. Ximelagatran—promises and concerns;Gurewich;JAMA,2005
4. Report from the French Transparence Commission on the Medical Benefit associated with melagatran and ximelagatran 6/16/2004, http://recherche.sante.gouv.fr/search97cgi/s97_cgi. Accessed March 20, 2005.
5. First launch for AstarZeneca's exanta™ (ximelagatran): the first oral anticoagulant in new class of direct thrombin inhibitors (DTIS) June 21, 2004. Company press release. Available at http://www.astrazeneca.com /archivelist/2004.aspx. Accessed on March 20, 2005.